Real-world ramucirumab and immune checkpoint inhibitor sequences in US patients with advanced gastroesophageal cancer-Reference-Cited by-同舟云学术

Real-world ramucirumab and immune checkpoint inhibitor sequences in US patients with advanced gastroesophageal cancer

Published:2023-06 Issue:18 Volume:19 Page:1277-1291
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Liepa Astra M¹^ORCID,Cui Zhanglin Lin¹,Beyrer Julie K¹,Hadden Elizabeth L¹²,Chatterjee Anindya¹

Affiliation:

1. Eli Lilly & Company, Lilly Corporate Center, Indianapolis, IN 46285, USA

2. DeLisle Associates LTD, Cranbrook DR, Indianapolis, IN 46250, USA

Abstract

Aim: To describe real-world treatment sequences of ramucirumab relative to immune checkpoint inhibitors (ICIs) in patients with advanced gastroesophageal cancer. Methods: Retrospective, observational study including adult patients treated with ramucirumab (April 2014–June 2020) from a nationwide health-record database. Results: In 1117 eligible patients, ramucirumab + paclitaxel was the most common ramucirumab-containing regimen (72.0%). A total of 217 patients also received an ICI. For ramucirumab then ICI (n = 148) and ICI then ramucirumab (n = 50), ramucirumab + taxane and ICI monotherapy were the most frequent approaches, most commonly observed as second- and third-line (2L and 3L). Median time on ramucirumab in 2L and 3L was similar regardless of sequence with ICI. Conclusion: Most patients with advanced gastroesophageal cancer received ramucirumab before ICI, with ramucirumab + paclitaxel as the most common ramucirumab-based regimen.

Funder

Eli Lilly and Company

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2022-0604

Reference36 articles.

1. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Stomach Cancer. Available on: https://seer.cancer.gov/statfacts/html/stomach.html (Accessed on 17 January 2022).

2. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Esophageal Cancer. Available on: https://seer.cancer.gov/statfacts/html/esoph.html (Accessed on 17 January 2022).

3. The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017

4. The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

5. National Comprehensive Care Network. Clinical Practice Guidelines in Oncology (NCCN Guidelines). Gastric Cancer Version 2.2022. Available on: www.nccn.org/professionals/physician_gls/pdf/gastric.pdf (Accessed on 17 Jan 2022).